Longitudinal profile of immunoglobulin G (IgG), IgM, and TgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus
Longitudinal profile of immunoglobulin G (IgG), IgM, and TgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus
复制标题
DOI：
10.1128/cdli.11.4.665-668.2004
复制
发表时间：
2004-07-01
期刊：
影响因子：
--
通讯作者：
Yuen, KY
中科院分区：
文献类型：
--
作者：
Woo, PCY;Lau, SKP;Yuen, KY
通过使用重组严重急性呼吸综合征冠状病毒（SARS-CoV）基于核衣壳蛋白的酶联免疫吸附试验（ELISA）和连续采集的血清标本（从症状发作后第0天到第240天），我们分析了SARS-CoV肺炎患者的免疫球蛋白G（IgG），IgM，SARS-CoV引起的肺炎患者的SARS-CoV核衣壳蛋白伊加抗体。对于IgG，在450 nm处的中值光密度（OD 450）在第17天变为阳性，并且观察到双相反应。在第240天，所有患者的抗核衣壳蛋白IgG抗体仍呈阳性。对于IgM，中位OD 450在第20.5天转为阳性，在约第80天达到峰值，并在约第180天降至基线水平以下。在第240天，36%的患者仍然是阳性的抗核衣壳蛋白IgM抗体。对于伊加，中位数OD 450在第17天转为阳性，在约第50天达到峰值，并在约第180天降至基线水平以下。在第240天，36%的患者仍然是阳性的抗核衣壳蛋白伊加抗体。重组SARS-CoV核衣壳蛋白ELISA检测血清阳转时间与间接免疫荧光法检测血清阳转时间相近。间接免疫荧光法检测IgG、IgM和伊加血清转化的中位时间分别为发病后17天（ELISA法为17天）、16.5天（ELISA法为20.5天）和17.5天（ELISA法为17天）。在6名死亡患者中，分别有1名、4名和1名患者未产生任何针对SARS冠状病毒核衣壳蛋白的IgG、IgM和伊加抗体，尽管通过间接免疫荧光试验在所有6名患者中均检测到这些抗体。SARS-CoV核衣壳蛋白抗体阳性是否具有预后意义有待进一步研究。
By using a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid protein-based enzyme-linked immunosorbent assay (ELISA) and serum specimens serially collected (from day 0 to day 240 after symptom onset) from patients with pneumonia due to SARS-CoV, we analyzed the longitudinal profiles of immunoglobulin G (IgG), IgM, and IgA antibodies against the SARS-CoV nucleocapsid protein in patients with pneumonia due to SARS-CoV. For IgG, the median optical density at 450 nm (OD450) turned positive at day 17 and a biphasic response was observed. At day 240, all patients were still positive for anti-nucleocapsid protein IgG antibody. For IgM, the median OD450 turned positive at day 20.5, peaked at about day 80, and fell to below the baseline level at about day 180. At day 240, 36% of the patients were still positive for anti-nucleocapsid protein IgM antibody. For IgA, the median OD450 turned positive at day 17, peaked at about day 50, and fell to below the baseline level at about day 180. At day 240, 36% of the patients were still positive for anti-nucleocapsid protein IgA antibody. The time of seroconversion detected by the recombinant SARS-CoV nucleocapsid protein-based ELISA and that detected by indirect immunofluorescence assay were similar. The median times of seroconversion for IgG, IgM, and IgA detected by the indirect immunofluorescence assay were 17 days (17 days by ELISA), 16.5 days (20.5 days by ELISA), and 17.5 days (17 days by ELISA), respectively, after disease onset. One, four, and one of the six patients who died did not produce any IgG, IgM, and IgA antibodies against the nucleocapsid protein of SARS-CoV, respectively, although these antibodies were detected in all six patients by the indirect immunofluorescence assay. Further studies should be performed to see whether SARS-CoV nucleocapsid protein antibody positivity has any prognostic significance.